CURRENT NEWS

• 15.06.2019
  Blueprint Medicines Presents Updated EXPLORER Trial Data for Avapritinib in Patients With Systemic Mastocytosis at 24th EHA Congress
• 15.06.2019
  CALQUENCE (Acalabrutinib) Significantly Prolonged the Time Patients Lived Without Disease Progression in Relapsed or Refractory Chronic Lymphocytic Leukemia
• 15.06.2019
  Forty Seven, Inc. Announces Updated Data From Phase 1b/2 Clinical Trial of 5F9 in Combination With Rituximab in Patients With Relapsed/Refractory Non-Hodgkin’s Lymphoma
• 15.06.2019
  Delays on Ebola = Death
• 15.06.2019
  Incyte Announces Positive Results From a Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo
• 15.06.2019
  Rapid Extension of CT Scanner Market During 2019-2028
• 15.06.2019
  Controlled Release Drug Delivery Market 2019- By Geographic Regions(North America, Europe, Asia Pacific, Latin America, Middle East & Africa)
• 15.06.2019
  Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-In-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-Cell Malignancies at the European Hematology Association Congress
• 14.06.2019
  GBT Announces Updated 24-Week Efficacy Data From All Patients Enrolled in Phase 3 HOPE Study Showing Statistically Significant and Sustained Improvements in Hemoglobin With Voxelotor
• 14.06.2019
  Novartis Continues to Innovate in CML With Long-Term Treatment-Free Remission Results Following Tasigna Use and Promising Combination Data With Investigational Compound Asciminib (ABL001)
• 14.06.2019
  Olainfarm Group Sales in May Increase by 20%
• 14.06.2019
  BeiGene Announces Clinical Results From Three Posters on Zanubrutinib Presented at the 24th Congress of European Hematology Association (EHA)
• 14.06.2019
  BeiGene Announces Updated Results From a Pivotal Phase 2 Study of Tislelizumab in Chinese Patients With Relapsed or Refractory Classical Hodgkin Lymphoma at the 24th Congress of the European Hematology Association (EHA)
• 14.06.2019
  Prometic Presents New Data on PBI-4050 and Its Mechanism of Action on Kidney Fibrosis at the 56th ERA/EDTA Congress
• 14.06.2019
  Sun Pharma Announces Late-Breaking Phase 2 Data Showing Potential of ILUMYA (Tildrakizumab-Asmn) to Improve Joint and Skin Symptoms of Psoriatic Arthritis
• 14.06.2019
  ArQule Announces Clinical Proof-Of-Concept Data From Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients With Relapsed/Refractory Hematologic Malignancies at the 2019 EHA Annual Meeting
• 14.06.2019
  Mawdsleys and Meabco Launch a Named Patient Supply Program for BP-C1
• 14.06.2019
  Zealand Pharma Increases Its Share Capital as a Consequence of Exercise of Employee Warrants
• 14.06.2019
  TLC Announces Part 1 Analysis of TLC590 Phase II Clinical Trial for Postsurgical Pain Management Following Bunionectomy
• 14.06.2019
  Chi-Med Announces That Surufatinib Phase III SANET-ep Study Has Met Its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early

Records per page:

Page

Total: 38538 records.